ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1258

Identification of a Spectrum of Therapeutic Targets of a New Treatment for Osteoarthritis Composed By Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract

Fanny Comblain1, Cécile Lambert1, Isabelle Lesponne2, Christelle Sanchez1, Jean-Emile Dubuc3 and Yves Henrotin4,5, 1University of Liège, Bone and Cartilage Research Unit, Arthropôle Liege, University of Liege, Liege, Belgium, 2Royal Canin Research Center, Aimargues, France, 3Clinical University Saint Luc, Orthopaedic Department, Clinical University Saint Luc, Brussels, Belgium, 4Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium, 5Bone and Cartilage Research Unit, Arthropôle Liege, University of Liege, Liege, Belgium

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The goal of treatment in OA is to reduce pain and improve function. There is no cure for the disease, but some attempts to slow the progression of the disease. We have previously demonstrated that a mixture of curcuminoids extract, hydrolyzed collagen and green tea extract (COT) inhibited inflammatory and catabolic mediator’s synthesis by osteoarthritic human chondrocytes in monolayer [1]. The objective of this study was to identify new targets of COT using genomic and proteomic approaches.

Methods: Enzymatically isolated primary human chondrocytes were cultured in monolayer until confluence and then incubated for 24 or 48 hours in the absence or in the presence of human interleukin-1β (10-11 M) and with or without COT, each compound at the concentration of 4 µg/ml. Microarray gene expression profiling between control (ctrl), COT, IL-1β and COT IL-1β conditions was performed. The biological relevance of regulated genes was determined with Ingenuity Pathway Analysis. Immunoassays (ELISA) were used to confirm the identified genes that were differentially expressed.

Results: 2549 genes were differentially expressed between ctrl and IL-1β conditions, 2280 genes were differentially expressed between IL-1β and COT IL-1β conditions and 1907 genes were differentially expressed between ctrl and COT conditions. The key regulated pathways were related to inflammation, cartilage metabolism and angiogenesis. In the inflammatory pattern, the IL‑1β stimulated chemokine (C-X-C motif) ligand 6 (CXCL6) gene expression and protein production were strongly down-regulated by COT (p<0.001). The most IL-1β up-regulated enzyme in the catabolic pattern was matrix metalloproteinase-13 (MMP-13). Both gene and protein were significantly down‑regulated by COT (p<0.001). The IL‑1β-stimulated bone morphogenetic protein-2 (BMP-2) gene expression and protein production were down-regulated by COT (p=0.001). In the angiogenesis pathway, one of the most up-regulated factors by IL-1β was stanniocalcin 1 (STC1) (p=0.005). This IL‑1β stimulating effect was significantly down‑regulated by COT (p<0.001). Moreover, COT significantly decreased STC1 production in basal condition (p=0.030). Finally, serpin E1 gene expression and protein production were down-regulated by IL‑1β (p<0.001). COT fully reversed the inhibitory effect of IL-1β (p=0.028). Serpin E1 gene expression was up-regulated by COT in basal condition (p<0.001).

Conclusion: The mixture COT has beneficial effect on OA physiopathology by regulating the synthesis of key catabolic, inflammatory and angiogenesis factors. These findings give a scientific rationale for the use of these natural ingredients in the management of OA. 

1.            Comblain F, Sanchez C, Lesponne I, Balligand M, Serisier S, Henrotin Y. Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract Synergically Inhibit Inflammatory and Catabolic Mediator’s Synthesis by Normal Bovine and Osteoarthritic Human Chondrocytes in Monolayer. PLoS One. 2015;10(3):e0121654.


Disclosure: F. Comblain, Royal Canin SAS, 2; C. Lambert, None; I. Lesponne, RandD Scientific Support Manager Royal Canin SAS, 3; C. Sanchez, None; J. E. Dubuc, None; Y. Henrotin, Artialis, Bioiberica, Danone, Expanscience, Ibsa, Merck, Pierre Fabre, Synolyne Pharma, Tilman, 5,Founder and President of Artialis SA and Synolyne Pharma, two spin-off companies of the University of Liege, 9.

To cite this abstract in AMA style:

Comblain F, Lambert C, Lesponne I, Sanchez C, Dubuc JE, Henrotin Y. Identification of a Spectrum of Therapeutic Targets of a New Treatment for Osteoarthritis Composed By Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-a-spectrum-of-therapeutic-targets-of-a-new-treatment-for-osteoarthritis-composed-by-curcuminoids-extract-hydrolyzed-collagen-and-green-tea-extract/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-a-spectrum-of-therapeutic-targets-of-a-new-treatment-for-osteoarthritis-composed-by-curcuminoids-extract-hydrolyzed-collagen-and-green-tea-extract/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology